News and Announcements
Imagion Biosystems announces positive results of its clinical trial data
- Published February 16, 2023 6:52AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imagion Biosystems (ASX: IBX) released this week the results of an independent review of their clinical trial data, which confirms that the company’s targeted imaging agent is safe and detectable by MRI machines. The company also announced it has dosed 9 patients in its Phase 1 HER2 breast cancer study still open for enrollment in four sites across Australia.
Guided by the clinical results, Imagion has decided to prioritize the development of its targeted nanoparticles in conjuncture with the existing MRI technology, as opposed to IBX’s proprietary MRX machines. With this shift in strategy, the company hopes to eliminate the near-term expense and risks associated with developing and introducing a new type of detection technology.
The company held a webinar yesterday to discuss the announcement with shareholders. The recording can be viewed here.
Sharing the full announcement with you to see if we can get an inclusion in WI’s next newsletter. It would be great to include the link to the recording in the company blurb to drive traffic to the site.
Connect with the company and learn more about Imagion Biosystems by accessing their deal room here.
Company Updates
Capital Flight or Policy Oversight? The $180M Seismic Shift Threatening Australian Innovation
A formal Senate submission by Wholesale Investor / CapitalHQ details the alarming real-world reactions of 260 founders and investors to proposed federal tax changes. With 91% of sophisticated investors scaling back local allocations and over $180M already paused or redirected offshore, the report warns of a structural funding crisis threatening the future of Australian deep tech, private equity, and startup innovation.
The Yield Illusion: Inside RAM’s Strategy to Withstand the Credit Shakeout
As interest rates reprice in 2026, the rush into private credit has created a dangerous trap for yield-hungry investors. Real Asset Management Group CEO Scott Kelly exposes the “yield illusion” dominating the market and explains why an origination-led, low-arrears mortgage strategy is the ultimate defense against an impending credit shakeout.
Office sector ‘unloved’ no more: Acure’s $80m Brisbane bet
While institutional investors remain wary of the office sector, Acure Asset Management is doubling down. Founder Angelo Del Borrello explains the “unloved” asset strategy behind his latest $80 million Brisbane acquisition and why the 2032 Olympics are creating a unique arbitrage opportunity for private syndicates.
Backed By Leading Investment Groups and Family Offices
